Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, hematological disorders and exposure to radiation.
Our vision is to leverage our advanced technology and our position as a global leader in cell therapy to develop, manufacture and market highly effective cell products that will heal patients around the world.
Our strategy is to develop powerful cell therapies that can be successfully commercialized to reach patients who need innovative treatment options. We develop placenta-derived, “off-the-shelf” products that do not require genetic or tissue matching prior to administration and could be delivered in almost any clinical setting. We design distinct cell products to target a variety of indications, and anticipate that a pipeline of differentiated products and indications will allow us to target large global markets. We explore new partnerships to advance our clinical development programs, while maintaining our strong commitment to current corporate, academic and government collaborations.
Pluristem's strategic advisory board: